Esophageal cancer-the five year survivors

Journal of Surgical Oncology

Volumn 103, Issue 2, 2011, Pages 179-183

  Kim, Tad ^a   Grobmyer, Stephen R ^a   Smith, Reshelle ^a   Ben David, Kfir ^a   Ang, Darwin ^a   Vogel, Stephen B ^a   Hochwald, Steven N ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

actual survival; cancer; esophageal

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; SURVIVOR; TUMOR DIFFERENTIATION;

AGED; BIOPSY; CARCINOMA; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS;

EID: 79251472762     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21784     Document Type: Article

References (24)

1. American Cancer Society: American Cancer Society: Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009.
2. Eloubeidi MA, Mason AC, Desmond RA, et al.: Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: A glimmer of hope ? Am J Gastroenterol 2003; 98: 1627-1633.
3. Allum WH, Stenning SP, Bancewicz J, et al.: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
4. Juergens RA, Forastiere A:, Combined modality therapy of esophageal cancer. JNCCN 2008; 6: 851-861.
5. Lv J, Cao XF, Zhu B, et al.: Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 2009; 15: 4962-4968.
6. Tepper J, Krasna MJ, Niedzwiecki D, et al.: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
7. Graham AJ, Shrive FM, Ghali WA, et al.: Defining the optimal treatment of locally advanced esophageal cancer: A systematic review and decision analysis. Ann Thorac Surg 2007; 83: 1257-1264.
8. Greer SE, Goodney PP, Sutton JE, et al.: Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 2005; 137: 172-177.
9. Fiorica F, Di Bona D, Schepis F, et al.: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004; 53: 925-930.
10. Urschel JD, Vasan H:, A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
11. Baba M, Aikou T, Natsugoe S, et al.: Appraisal of ten-year survival following esophagectomy for carcinoma of the esophagus with emphasis on quality of life. World J Surg 1997; 21: 282-286.
12. Gockel I, Gonner U, Domeyer M, et al.: Long-term survivors of esophageal cancer: Disease-specific quality of life, general health and complication. J Surg Oncol 2010; 102: 516-522.
13. Portale G, Hagen JA, Peters JH, et al.: Modern 5-year survival of resectable esophageal adenocarcinoma: Single institution experience with 263 patients. J Am Coll Surg 2006; 202: 588-596.
14. Sarbia M:, The histological appearance of oesophageal adenocarcinoma-an analysis based on 215 resection specimens. Virchows Arch 2006; 448: 532-538.
15. Hammoud ZT, Kesler KA, Ferguson MK, et al.: Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus 2006; 19: 69-72.
16. Donahue JM, Nichols FC, Li Z, et al.: Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87: 392-399.
17. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al.: Minimally invasive esophagectomy: Outcomes in 222 patients. Ann Surg 2003; 238: 486-494.
18. Abate E, DeMeester SR, Zehetner J, et al.: Recurrence after esophagectomy for adenocarcinoma: Defining optimal follow up intervals and testing. J Am Coll Surg 2010; 210: 428-435.
19. Raghunathan TE, van Hoewyk J, Solenbeger P:, A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001; 27: 85-95.
20. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337.
21. Rizk NP, Bach PB, Schrag D, et al.: The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg 2004; 198: 42-50.
22. Pennathur A, Luketich JD, Landreneau RJ, et al.: Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg 2008; 85: 1930-1936.
23. Leers JM, Ayazi S, Hagen JA, et al.: Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: Evidence for downstaging of N status. J Am Coll Surg 2009; 208: 553-556.
24. Hochwald SN, Kim S, Klimstra DS, et al.: Analysis of 154 actual five year survivors of gastric cancer. J Gastrointest Surg 2000; 4: 520-525.